Abstract Obese patients are characterised by several neuroendocrine abnormalities, including characteristically a decrease in growth hormone responsiveness to GH-releasing hormone. In normal subjects, the GH response to GHRH is enhanced by the acetylcholinesterase inhibitor, pyridostigmine. We have studied the effect of this drug on GH secretion in gross obesity. Twelve obese patients were studied (mean weight 156% of ideal) and compared with a group of 8 normal volunteers. Each subject was initially studied on two occasions, in random order, with GHRH (1-29) NH2 100 \g=m\g iv alone and following pretreatment with pyridostigmine 120 mg orally one hour prior to GHRH. In obese patients, the GH response to GHRH was significantly blunted when compared to controls (GH peak: 20 \ m=+-\4 vs 44 \m=+-\16 \g=m\g/l ; mean \ m=+-\ sem). After pyridostigmine, the response to GHRH was enhanced in the obese subjects, but remained significantly reduced compared to non-obese subjects treated with GHRH and pyridostigmine (GH peak: 30 \ m=+-\5 vs 77 \ m=+-\20 \g=m\g/l ,respectively). In 6 subjects, higher doses of GHRH or pyridostigmine did not further increase GH responsiveness in obese patients. Our (23, 24) .
lowing pretreatment with pyridostigmine 120 mg orally one hour prior to GHRH. In obese patients, the GH response to GHRH was significantly blunted when compared to controls (GH peak: 20 \ m=+-\4 vs 44 \m=+-\16 \g=m\g/l ; mean \ m=+-\ sem). After pyridostigmine, the response to GHRH was enhanced in the obese subjects, but remained significantly reduced compared to non-obese subjects treated with GHRH and pyridostigmine (GH peak: 30 \ m=+-\5 vs 77 \ m=+-\20 \g=m\g/l ,respectively). In 6 subjects, higher doses of GHRH or pyridostigmine did not further increase GH responsiveness in obese patients. Our results suggest that obese patients have a disturbed cholinergic control of GH release, probably resulting from increased somatostatinergic tone. This disturbed regulation may be responsible, at least in part, for the blunted GH responses to provocative stimuli.
Obese patients have blunted growth hormone re¬ sponses to a wide variety of stimuli (1) (2) (3) (4) (5) (6) (7) (8) . It has also been shown that these patients have decreased GH responses to GH-releasing hormone (9) (10) (11) (12) (13) (14) (16) and increased hypothalamic somatostatin release in vitro (17) . However, there is little direct evidence in the human.
Pyridostigmine is a drug which activates cholinergic receptors by decreasing the activity of acetylcholinesterase, and enhances GH responsiveness to GHRH (18) (19) (20) (21) ; this is considered to occur via the inhibition of hypothalamic somatostatin (22) . Recent In order to investigate whether any differences found were related to drug dosage, 6 obese subjects were also submitted to a further two tests, one with placebo tablets plus 300 ng GHRH (1-29) NH2, and another with 180 mg pyridostigmine and 100 ng GHRH NH2, following the same protocol described above.
GH assay
Serum GH was measured in duplicate by a double-anti¬ body radioimmunoassay as previously described (25 Undetectable GH levels (<1.
Results
In normal subjects, GH rose significantly after GHRH, and this response was significantly en¬ hanced by pyridostigmine (Fig. 1) 16 |xg/l> respectively; p<0.02; Fig. 1 ). Following pyridostigmine, the GH response to GHRH in obese subjects was enhanced signifi¬ cantly between 15 and 75 min after GHRH, and was not different from the placebo-treated controls (peak GH values: 30 ± 5 |ig/l). However, in the obese subjects the GH response to GHRH after pyridostigmine (both peak response and the area under the curve) was reduced when compared to normals treated with GHRH and pyridostigmine (Fig. 1) . A negative correlation between peak GH levels after GHRH and percentage ideal body weight was found in obese subjects treated with both placebo (r= -0.70, p<0.01) and pyridostig¬ mine (r= -0.81 ; p<0.005). Higher doses of GHRH did not further increase GH responsiveness in obese subjects ( Fig. 2) . With the higher dose of pyridostigmine (180 mg), the peak serum GH was slightly but non-significantly higher than with 120 Change in mean serum GH (± sem) in 6 obese subjects given GHRH 100 ng ¡v following pre-treatment with py¬ ridostigmine 120 mg (o) or 180 mg (•).
mg; however, it was still less than that seen in the normal subjects ( Fig. 3) . Adverse effects were mild in all patients. All sub¬ jects had facial flushing after GHRH 100 |xg, which was accentuated with the higher dose. The princi¬ pal adverse reactions associated with pyridostig¬ mine were colicky abdominal pain in 44% and diz¬ ziness in 27%. The higher dose of pyridostigmine did not cause any increase in frequency or intensity of adverse reactions.
Discussion
Our results confirm that obese patients show a sig¬ nificantly blunted GH response to GHRH which is inversely related to body weight, as previously re¬ ported by other workers (9, 10) . They also demon¬ strate that pyridostigmine increases the response of GH to GHRH in obesity, suggesting that cholinergic mechanisms may be involved in this process. Enhancement of GH responsiveness to GHRH also suggests that somatotropes are functionally normal in obese patients.
These results are essentially in agreement with recent data from two studies in adults (23, 24) , and one in obese children (26 (18, 19, (27) (28) (29) (30) (31) , and pyri¬ dostigmine enhances the GH response to supramaximal doses of GHRH (21) . The (29, 32, 33) , although this has not been uniformly found (34) . However, studies in the rat in vivo found that cholinergic modulation of GHRH-in¬ duced GH release did not occur when the animals were treated with cysteamine or were submitted to deafferentation of the mediobasal hypothalamus, procedures which decrease hypothalamic somatostatin concentrations (22) . Furthermore, in vitro studies have shown that acetylcholine inhibits somatostatin release from hypothalamic fragments (35) . Therefore (17) . Chronic inhibition of somatotropes by an excess of somatostatin may be an alternative related expla¬ nation. Further studies using repetitive administra¬ tion of GHRH plus pyridostigmine may help elu¬ cidate this problem.
In conclusion, our results suggest that inhibition of GHRH-induced GH release in obesity is, at least in part, due to an increase in hypothalamic soma¬ tostatin release. This may in turn reflect changes in cholinergic control, although other neurotransmitters might also be involved in this process.
